Blog
    Regulatory UpdateFor PhysiciansJuly 14, 2026

    FDA peptide compounding status and safety signals

    Review FDA Category 2 status for BPC-157 and TB-500, clinical trial data for semaglutide and tirzepatide, and emerging post-marketing safety signals.

    Clinical Question

    What is the current regulatory standing and safety profile of commonly used peptides according to FDA compounding categories, warning letters, and post-marketing safety signals?

    Evidence Snapshot

    • Total Adverse Event Reports: 187,757 GLP-1 RA reports for semaglutide through 2023.
    • FDA Status: Multiple peptides (BPC-157, TB-500, Ipamorelin) classified as Category 2 bulk substances.
    • Clinical Efficacy (Semaglutide): 14.9% weight loss (STEP 1) and 20% MACE reduction (SELECT).
    • Clinical Efficacy (Tirzepatide): 22.5% weight loss (SURMOUNT-1).
    • Regulatory Grading: BPC-157, TB-500, and others assigned Category 2 status due to immunogenicity concerns and lack of safety data.

    What the Research Shows

    Evidence from clinical trials supports significant weight loss and cardiovascular risk reduction for FDA-approved GLP-1 receptor agonists. In the STEP 1 trial (NCT03548935), semaglutide demonstrated 14.9% weight loss, while the SELECT trial (NCT03574597) documented a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated 22.5% weight loss in the SURMOUNT-1 trial (NCT04184622) and showed superiority in the SURMOUNT-5 head-to-head trial against semaglutide.

    Conversely, research evidence for other peptides is less definitive or restricted to non-US contexts. Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, returned negative results in a Phase III sepsis trial (NCT02867267) regarding mortality reduction. Retatrutide is currently in Phase III trials (TRIUMPH-3) following a Phase II finding of 24.2% weight loss at a 12mg dose. Selank and Semax maintain regulatory approval in Russia, the latter specifically for stroke.

    Mechanism

    The provided data does not contain specific biochemical mechanism of action data for these peptides. For semaglutide safety signals, the mechanism of delayed gastric emptying is noted as a contributing factor to pulmonary aspiration risk and impacts on oral medication absorption.

    Limitations of the Evidence

    The regulatory landscape for compounded peptides is significantly constrained by data gaps. The FDA cites a lack of human exposure data and general safety data for TB-500. BPC-157 is restricted due to immunogenicity concerns and a lack of established safety data.

    For semaglutide, several safety signals are currently under evaluation. Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) is an emerging signal under EMA review as of January 2025 (96 cases identified through Dec 2024). While suicidal ideation is listed in Section 5.9 of the label, current data does not support a higher risk compared to background rates. Additionally, intestinal obstruction (ileus) and pulmonary aspiration were added to labeling only post-marketing, reflecting the limitations of initial clinical trial detection for rare adverse events.

    Clinical Takeaway

    As of March 2026, the FDA has categorized BPC-157, TB-500, and GHK-Cu as Category 2 bulk substances, rendering them ineligible for routine compounding due to safety risks and immunogenicity concerns. Several other substances, including Ipamorelin, AOD-9604, and CJC-1295, have had their nominations withdrawn or were removed from compounding eligibility in September 2024. For semaglutide, clinical monitoring is warranted for gastrointestinal effects (pancreatitis, ileus), hepatobiliary issues associated with rapid weight loss, and emerging signals such as NAION and pulmonary aspiration during anesthesia.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

    Sources

    • FDA Regulatory Status Records: ID 0abdad3c, 68b0b103, c8181049, 96fb1240, 1a160b34, 116a4f32, 856316f2, fe228995, a11f0210, a6e75c1b.
    • FAERS Safety Signals: ID 502f8ab5, 0296a263, d2135902, 4f021484, 3c2b6572, bcece5fd, afc343ed, be753983, 99f7d6d6, 60c7beaa.
    • Clinical Trial Records: NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT059290, NCT00451282, NCT02867267.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1tb 500

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.